Changes in trend of antipsychotics prescription in patients treated with cholinesterase inhibitors after warnings from Italian Medicines Agency. Results from the EPIFARM-Elderly Project

Carlotta Franchi, Mauro Tettamanti, Alessandra Marengoni, Francesca Bonometti, Luca Pasina, Laura Cortesi, Ida Fortino, Angela Bortolotti, Luca Merlino, Ugo Lucca, Emma Riva, Alessandro Nobili

Research output: Contribution to journalArticle

Abstract

The objective of the study was to assess the trend of antipsychotic prescription in elderly patients taking cholinesterase inhibitors (ChEIs) from 2002 to 2008 and the changes subsequent to two main official warnings issued by the Italian Medicines Agency to restrict their use. Elderly patients aged 65-94. years who received at least one prescription of ChEIs between 1 January 2002 and 31 December 2008 were selected. We used data on prescriptions from the Lombardy Region Drug Administrative Database (Italy). The first prescription of one ChEI was used as the index day to calculate the prescription of an antipsychotic. The prescription of atypical antipsychotics in patients exposed to ChEIs declined from 21.0% in 2002 to 14.6% in 2008 (OR 0.92; 95%CI:0.90, 0.94; p <0.001), while the prescribing prevalence of typicals slightly increased (OR 1.08; 95%CI:1.03, 1.13; p = 0.001). In relation to the two warnings, the prevalence of patients who received a prescription of antipsychotics was significantly lower in 2005 than 2004 (23.1% vs. 28.0%; OR 0.79; 95%CI:0.73-0.86; p <0.001) and in 2007 than 2006 (19.4% vs. 23.0%; OR 0.79; 95%CI:0.73-0.86; p <0.001). After the first safety warning the prevalence of prescriptions for risperidone and olanzapine dropped significantly, and there was a significant increase for quetiapine. Haloperidol prescriptions increased, especially after the second warning. Despite regulatory warnings issued to discourage the use of antipsychotics, they are still frequently prescribed to patients taking ChEIs. Awaiting further studies to clarify their therapeutic role, physicians should prescribe antipsychotics very cautiously and only after careful risk-benefit assessment.

Original languageEnglish
Pages (from-to)569-577
Number of pages9
JournalEuropean Neuropsychopharmacology
Volume22
Issue number8
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Cholinesterase Inhibitors
Antipsychotic Agents
Prescriptions
olanzapine
Pharmaceutical Databases
Physician's Role
Risperidone
Haloperidol
Italy
Safety

Keywords

  • Antipsychotic drugs
  • Cholinesterase inhibitors
  • Elderly
  • Treatment trends

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Biological Psychiatry
  • Neurology
  • Pharmacology

Cite this

Changes in trend of antipsychotics prescription in patients treated with cholinesterase inhibitors after warnings from Italian Medicines Agency. Results from the EPIFARM-Elderly Project. / Franchi, Carlotta; Tettamanti, Mauro; Marengoni, Alessandra; Bonometti, Francesca; Pasina, Luca; Cortesi, Laura; Fortino, Ida; Bortolotti, Angela; Merlino, Luca; Lucca, Ugo; Riva, Emma; Nobili, Alessandro.

In: European Neuropsychopharmacology, Vol. 22, No. 8, 08.2012, p. 569-577.

Research output: Contribution to journalArticle

Franchi, Carlotta ; Tettamanti, Mauro ; Marengoni, Alessandra ; Bonometti, Francesca ; Pasina, Luca ; Cortesi, Laura ; Fortino, Ida ; Bortolotti, Angela ; Merlino, Luca ; Lucca, Ugo ; Riva, Emma ; Nobili, Alessandro. / Changes in trend of antipsychotics prescription in patients treated with cholinesterase inhibitors after warnings from Italian Medicines Agency. Results from the EPIFARM-Elderly Project. In: European Neuropsychopharmacology. 2012 ; Vol. 22, No. 8. pp. 569-577.
@article{5b764a786bd74039acab81dbb2863272,
title = "Changes in trend of antipsychotics prescription in patients treated with cholinesterase inhibitors after warnings from Italian Medicines Agency. Results from the EPIFARM-Elderly Project",
abstract = "The objective of the study was to assess the trend of antipsychotic prescription in elderly patients taking cholinesterase inhibitors (ChEIs) from 2002 to 2008 and the changes subsequent to two main official warnings issued by the Italian Medicines Agency to restrict their use. Elderly patients aged 65-94. years who received at least one prescription of ChEIs between 1 January 2002 and 31 December 2008 were selected. We used data on prescriptions from the Lombardy Region Drug Administrative Database (Italy). The first prescription of one ChEI was used as the index day to calculate the prescription of an antipsychotic. The prescription of atypical antipsychotics in patients exposed to ChEIs declined from 21.0{\%} in 2002 to 14.6{\%} in 2008 (OR 0.92; 95{\%}CI:0.90, 0.94; p <0.001), while the prescribing prevalence of typicals slightly increased (OR 1.08; 95{\%}CI:1.03, 1.13; p = 0.001). In relation to the two warnings, the prevalence of patients who received a prescription of antipsychotics was significantly lower in 2005 than 2004 (23.1{\%} vs. 28.0{\%}; OR 0.79; 95{\%}CI:0.73-0.86; p <0.001) and in 2007 than 2006 (19.4{\%} vs. 23.0{\%}; OR 0.79; 95{\%}CI:0.73-0.86; p <0.001). After the first safety warning the prevalence of prescriptions for risperidone and olanzapine dropped significantly, and there was a significant increase for quetiapine. Haloperidol prescriptions increased, especially after the second warning. Despite regulatory warnings issued to discourage the use of antipsychotics, they are still frequently prescribed to patients taking ChEIs. Awaiting further studies to clarify their therapeutic role, physicians should prescribe antipsychotics very cautiously and only after careful risk-benefit assessment.",
keywords = "Antipsychotic drugs, Cholinesterase inhibitors, Elderly, Treatment trends",
author = "Carlotta Franchi and Mauro Tettamanti and Alessandra Marengoni and Francesca Bonometti and Luca Pasina and Laura Cortesi and Ida Fortino and Angela Bortolotti and Luca Merlino and Ugo Lucca and Emma Riva and Alessandro Nobili",
year = "2012",
month = "8",
doi = "10.1016/j.euroneuro.2011.12.009",
language = "English",
volume = "22",
pages = "569--577",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier Science B.V.",
number = "8",

}

TY - JOUR

T1 - Changes in trend of antipsychotics prescription in patients treated with cholinesterase inhibitors after warnings from Italian Medicines Agency. Results from the EPIFARM-Elderly Project

AU - Franchi, Carlotta

AU - Tettamanti, Mauro

AU - Marengoni, Alessandra

AU - Bonometti, Francesca

AU - Pasina, Luca

AU - Cortesi, Laura

AU - Fortino, Ida

AU - Bortolotti, Angela

AU - Merlino, Luca

AU - Lucca, Ugo

AU - Riva, Emma

AU - Nobili, Alessandro

PY - 2012/8

Y1 - 2012/8

N2 - The objective of the study was to assess the trend of antipsychotic prescription in elderly patients taking cholinesterase inhibitors (ChEIs) from 2002 to 2008 and the changes subsequent to two main official warnings issued by the Italian Medicines Agency to restrict their use. Elderly patients aged 65-94. years who received at least one prescription of ChEIs between 1 January 2002 and 31 December 2008 were selected. We used data on prescriptions from the Lombardy Region Drug Administrative Database (Italy). The first prescription of one ChEI was used as the index day to calculate the prescription of an antipsychotic. The prescription of atypical antipsychotics in patients exposed to ChEIs declined from 21.0% in 2002 to 14.6% in 2008 (OR 0.92; 95%CI:0.90, 0.94; p <0.001), while the prescribing prevalence of typicals slightly increased (OR 1.08; 95%CI:1.03, 1.13; p = 0.001). In relation to the two warnings, the prevalence of patients who received a prescription of antipsychotics was significantly lower in 2005 than 2004 (23.1% vs. 28.0%; OR 0.79; 95%CI:0.73-0.86; p <0.001) and in 2007 than 2006 (19.4% vs. 23.0%; OR 0.79; 95%CI:0.73-0.86; p <0.001). After the first safety warning the prevalence of prescriptions for risperidone and olanzapine dropped significantly, and there was a significant increase for quetiapine. Haloperidol prescriptions increased, especially after the second warning. Despite regulatory warnings issued to discourage the use of antipsychotics, they are still frequently prescribed to patients taking ChEIs. Awaiting further studies to clarify their therapeutic role, physicians should prescribe antipsychotics very cautiously and only after careful risk-benefit assessment.

AB - The objective of the study was to assess the trend of antipsychotic prescription in elderly patients taking cholinesterase inhibitors (ChEIs) from 2002 to 2008 and the changes subsequent to two main official warnings issued by the Italian Medicines Agency to restrict their use. Elderly patients aged 65-94. years who received at least one prescription of ChEIs between 1 January 2002 and 31 December 2008 were selected. We used data on prescriptions from the Lombardy Region Drug Administrative Database (Italy). The first prescription of one ChEI was used as the index day to calculate the prescription of an antipsychotic. The prescription of atypical antipsychotics in patients exposed to ChEIs declined from 21.0% in 2002 to 14.6% in 2008 (OR 0.92; 95%CI:0.90, 0.94; p <0.001), while the prescribing prevalence of typicals slightly increased (OR 1.08; 95%CI:1.03, 1.13; p = 0.001). In relation to the two warnings, the prevalence of patients who received a prescription of antipsychotics was significantly lower in 2005 than 2004 (23.1% vs. 28.0%; OR 0.79; 95%CI:0.73-0.86; p <0.001) and in 2007 than 2006 (19.4% vs. 23.0%; OR 0.79; 95%CI:0.73-0.86; p <0.001). After the first safety warning the prevalence of prescriptions for risperidone and olanzapine dropped significantly, and there was a significant increase for quetiapine. Haloperidol prescriptions increased, especially after the second warning. Despite regulatory warnings issued to discourage the use of antipsychotics, they are still frequently prescribed to patients taking ChEIs. Awaiting further studies to clarify their therapeutic role, physicians should prescribe antipsychotics very cautiously and only after careful risk-benefit assessment.

KW - Antipsychotic drugs

KW - Cholinesterase inhibitors

KW - Elderly

KW - Treatment trends

UR - http://www.scopus.com/inward/record.url?scp=84864570991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864570991&partnerID=8YFLogxK

U2 - 10.1016/j.euroneuro.2011.12.009

DO - 10.1016/j.euroneuro.2011.12.009

M3 - Article

C2 - 22297160

AN - SCOPUS:84864570991

VL - 22

SP - 569

EP - 577

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 8

ER -